anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intermittent hypoxia (IH) has been extensively studied in recent years, demonstrating adverse and beneficial effects on several physiological systems. However, the precise mechanism underlying its cardiac effects on the heart remains unclear. This study aims to explore the effect of treatment on atrial fibrillation under IH conditions, providing data that can potentially be used in the treatment of heart disease. An atrial fibrillation (AF) model was induced by injecting monocrotaline (MCT, 60 mg/kg) into rats. The study included 32 rats divided into four groups: Control, Control + IH, AF, and AF + IH. We evaluated molecular changes associated with AF using ELISA and Western blot and performed electrophysiological experiments to evaluate AF. Arrhythmia-related calcium and fibrosis markers were investigated. Phosphorylation levels of CaMKII, Phospholamban, and RyR2 all increased in the AF group but decreased in the IH-exposed group. Additionally, fibrosis marker expressions such as SMA, MMP2, MMP9, and TGF-β increased in the AF group but were significantly downregulated with IH treatment. Connexin 43 and AQP4 expression were restored in the IH-treated group. These findings suggest that IH may prevent AF by downregulating the expression of calcium-handling proteins and fibrosis-associated proteins in an AF-induced rat model.
PURPOSE: We aimed to explore the clinical characteristics of Campylobacter bacteraemia and identify the trends, risk factors for mortality, and antimicrobial susceptibility patterns from clinical samples.
METHODS: This retrospective cohort study included patients confirmed to have Campylobacter bacteraemia from seven hospitals between January 2010 and June 2021. Data on demographics and underlying history, clinical manifestation, and antimicrobial susceptibility patterns were collected and analyzed. Annual cases of Campylobacter enteritis were extracted from a public database.
RESULTS: A total of 108 patients were included, and five species were isolated. Campylobacter jejuni accounted for 54 (50.0%) cases and 17 (16%) patients had no symptoms other than fever. In-hospital mortality occurred in 14 (13.0%) patients. C. jejuni bacteraemia was associated with lower mortality compared to non-C. jejuni bacteraemia. Underlying cancer and septic shock were the significant factors associated with in-hospital mortality. Quinolone resistance was high (59%), whereas only 4% of isolates exhibited macrolide resistance. There has been a significant increase in the number of Campylobacter enteritis cases, which was strongly correlated with the number of Campylobacter bacteraemia cases (Pearson's coefficient: 0.953; p < 0.0001).
CONCLUSION: The notably increasing incidence of Campylobacter bacteraemia and antibiotic resistance patterns can challenge the treatment, necessitating collective efforts of national surveillance and networks by many departments.
FIELD: medicine, immunology. SUBSTANCE: alcohol precipitate B of human plasma blood is diluted in 15- 20 volumes of 0.005-0.01 M sodium chloride solution at pH 5.3-5.6, ethyl alcohol is added to final concentration 13-17% at temperature (0 C) (-4 C), precipitate is separated, pH value is brought about to 6.8-7.2 and ethyl alcohol is added to final concentration 24-26%. Precipitate is separated by centrifugation, dissolved in 10-15 volumes of 0.005-0.01 M sodium chloride solution at pH 5.3-5.6 and ethyl alcohol is added to final concentration 13-17%. Inert precipitate is separated by centrifugation, pH value of supernatant is brought about to 6.9 ± 01 and ethyl alcohol is added to final concentration 24-26% at temperature (-4 C) (-10 C). Precipitate of end product is isolated by centrifugation, dissolved in water followed by sterilizing filtration and solution is kept at temperature (+1 C) (+15 C) for 1 week 1 month. Precipitate is removed by sterilizing filtration and low-molecular impurities are removed by ultrafiltration. Invention can be used for immunotherapy and immunoprophylaxis of bacterial and viral infections. EFFECT: enhanced purity degree of end product. 2 ex
Treatment starts with four cycles of neoadjuvant FOLFIRINOX chemotherapy every two weeks, combined with pembrolizumab every six weeks, starting at the same day as the second cycle of FOLFIRINOX. Restaging is performed after cycle 4 of FOLFIRINOX with a CT-scan. Patients with a response or stable disease will undergo SABR 5 X 8 Gy followed by an additional four cycles FOLFIRNOX chemotherapy, combined with pembrolizumab. Restaging is repeated after 8 cycles FOLFRINOX in total. Patients undergo a surgical exploration if they have non-metastatic borderline resectable disease on CT-scan of the chest and abdomen, 3-6 weeks after completion of chemotherapy. Patients also proceed to surgical exploration if they discontinue neoadjuvant FOLFIRINOX and/or pembrolizumab because of toxicity or have local progression at restaging within criteria for borderline resectable disease.
BACKGROUND: According to the new AASLD Practice Guidance, all patients with primary sclerosing cholangitis (PSC) should be considered for participation in clinical trials. However, PSC's rarity has posed challenges to characterizing patient interest in trial participation and identifying predictors of patient willingness to participate in drug trials.
METHODS: PSC Partners Seeking a Cure developed the "Our Voices" survey to inform the development of the Externally-Led Patient-Focused Drug Development Forum, an FDA initiative to capture patient experiences and perspectives on drug development.
RESULTS: Of 797 survey respondents from over 30 countries, 536 (67%) identified slowing disease progression as the most important outcome. Eighty-nine percent identified their hepatologist/gastroenterologist as someone they would approach for advice about trials. Although 61% reported being willing to participate in drug trials, only 26% had ever been asked to participate. Notable barriers to trial involvement included unknown long-term risks (71%), long travel times to the study center (32%), and a liver biopsy requirement (27%). On multivariable logistic regression, pruritus (OR 1.62, 95% CI: 1.09-2.40, p = 0.017) was positively associated with willingness to participate in disease-modifying therapy trials, while jaundice (OR 0.34, 95% CI: 0.19-0.61, p < 0.001) and inflammatory bowel disease (OR 0.64, 95% CI: 0.42-0.98, p = 0.038) were negatively associated. Pruritus (OR 2.25, 95% CI: 1.50-3.39, p < 0.001) was also independently associated with willingness to participate in symptom treatment trials.
CONCLUSIONS: Most patients with PSC report interest in participating in clinical trials, but few have been asked to participate. Referral of patients with PSC by their hepatologist/gastroenterologist to clinical trials and patient education on trial participation are vital to closing the gap between trial interest and participation. Pruritus may serve as a key indicator of patient interest in trial participation.
Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
ABSORICA/ABSORICA LD is contraindicated in pregnancy [see Contraindications (4.1)]. Based on human data, ABSORICA/ABSORICA LD can cause fetal harm when administered to a pregnant patient. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of ABSORICA/ABSORICA LD even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. Major congenital malformations, spontaneous abortions, and premature births have been documented following exposure to isotretinoin during pregnancy [see Use in Specific Populations (8.1)].

If a pregnancy occurs during ABSORICA/ABSORICA LD treatment, discontinue ABSORICA/ABSORICA LD immediately and refer the patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Any suspected fetal exposure during or 1 month after ABSORICA/ABSORICA LD therapy must be reported immediately to the FDA via the MedWatch telephone number 1-800-FDA-1088, and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet (www.ipledgeprogram.com).

Patients must be informed not to donate blood during ABSORICA/ABSORICA LD therapy and for 1 month following discontinuation because the blood might be given to a pregnant patient whose fetus must not be exposed to isotretinoin.

ABSORICA/ABSORICA LD is available only through a restricted program under a REMS [see Warnings and Precautions (5.2)].
Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score \<30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument. A follow-up visit after 2-4 weeks is scheduled for oral hygiene control and re-motivation/re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining probing pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
Patients receive oral everolimus once daily on days 1-28. Patients also receive leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
OBJECTIVES: Children with certain congenital anomalies of the kidney and urinary tract and neurogenic bladder (CAKUT/NGB) are at higher risk of treatment failure for urinary tract infections (UTIs) than children with normal genitourinary anatomy, but the literature describing treatment and outcomes is limited. The objectives of this study were to describe the rate of treatment failure in children with CAKUT/NGB and compare duration of antibiotics between those with and without treatment failure.
METHODS: Multicenter retrospective cohort of children 0 to 17 years old with CAKUT/NGB who presented to the emergency department with fever or hypothermia and were diagnosed with UTI between 2017 and 2018. The outcome of interest was treatment failure, defined as subsequent emergency department visit or hospitalization for UTI because of the same pathogen within 30 days of the index encounter. Descriptive statistics and univariates analyses were used to compare covariates between groups.
RESULTS: Of the 2014 patient encounters identified, 482 were included. Twenty-nine (6.0%) of the 482 included encounters had treatment failure. There was no difference in the mean duration of intravenous antibiotics (3.4 ± 2.5 days, 3.5 ± 2.8 days, P = .87) or total antibiotics between children with and without treatment failure (10.2 ± 3.8 days, 10.8 ± 4.0 days, P = .39) Of note, there was a higher rate of bacteremia in children with treatment failure (P = .04).
CONCLUSIONS: In children with CAKUT/NGB and UTI, 6.0% of encounters had treatment failure. Duration of antibiotics was not associated with treatment failure. Larger studies are needed to assess whether bacteremia modifies the risk of treatment failure.
A DNA sequence is described for the gene therapy of diseases associated with the immune system. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated in a cell-specific or virus-specific manner and this activation is regulated by the promoter module in a cell cycle-specific manner. The choice of activator sequence and active substance depends on the indication area. The DNA sequence is inserted into a viral or non-viral vector which is supplemented by a ligand having affinity for the target cell. Depending on the choice of activator sequence and active substance, the following can be treated by administering the DNA sequence: defective formation of blood cells; autoimmune diseases and allergies and, in addition, rejection reactions against transplanted organs; chronic arthritis; viral and parasitic infections and, in addition, prophylaxis of viral, bacterial and parasitic infections; and leukemias.
Persistent pulmonary hypertension of the newborn (PPHN) is a condition in which the pulmonary vasculature fails to relax after birth resulting in severe hypoxemia. This condition has a high rate of mortality and morbidity. The current standard of care is treatment with inhaled nitric oxide (iNO). However, for many babies this treatment does not provide sufficient improvement in oxygenation.

In this study, subjects already receiving nitric oxide will be randomized to one of two dosing regimens of milrinone. They will receive milrinone IV for 24 hours and will be monitored for 24 hours afterwards. During this time, milrinone assays will be performed by blood sampling. Echocardiograms will also be performed to explore the pharmacodynamics of milrinone. Safety monitoring will be performed.
Tucatinib + trastuzumab + pembrolizumab + CAPOX. Tucatinib, trastuzumab, and CAPOX given in 21-day cycles and pembrolizumab given in 42-day cycles.
The participation to the national screening program for colorectal cancer in France is low. In order to improve the performances of its organized program, the National Cancer Institute is planning to modify the invitation procedure. This is a pilot project and if an improvement in the program performances is reported, the invitation procedure may be scaled up.

Eligible individuals for colorectal cancer screening will be identified by the Regional Cancer Screening Coordinating Centre and randomized into the intervention or control arms. They will be followed for FIT test submission to the central laboratory (participation to screening). Those who did not send their test will receive reminder letters. Those who had a positive FIT test will be followed up for coloscopy referral, and result of the coloscopy. Comparison of the participation rates to screening program and to coloscopy among those with a positive FIT test will be compared between the two study arms.
Participants take part in a n-of-1 design. They are first required to consume their habitual diet, for one week, followed by a period of dietary advice, for two weeks.
Dual-task training will consist of balancing on the dynamic stability platform and responding to auditory stimuli. Participants will perform 18 trials total in 3 blocks of 6 trials. Each trial will be 30 seconds (s) in duration followed by 30 s of rest (i.e. quiet standing on the platform while holding onto the rails.) Between each training block, the participant will step off the platform and rest for 2 minutes. Dual-task training will occur on consecutive visits 2-6.
The prospective treatment group will have an anesthetic induction according to the anesthetic provider's preference that will include propofol and fentanyl as IV induction agents and rocuronium as a muscle paralytic. Maintenance of anesthesia for the treatment group will include sevoflurane with a target end tidal concentration of 1-1.5%, rocuronium as a paralytic as needed, opioids and any other standard medication deemed necessary by the provider.
An X-ray emitted from an X-ray tube (12) and transmitted through an object (10) is imaged by an image intensifier (14) and a TV camera (18) to obtain an X-ray fluorogram. Angiography is performed prior to PTCA. An output from the TV camera (18) during angiography is written as road map images in an image memory (26). During PTCA, the X-ray fluorogram obtained from the TV camera (18) is supplied to a display (30) through a buffer memory (24). An output from the image memory (26) is supplied to a display (34). Read/write access of the image memory (26) is controlled by a read/write controller (38) which receives an output electro­cardiogram from an electrocardiograph (36). A plurality of road map images are stored at equal time intervals within one heart beat period from a timing at which the electrocardiogram represents an R-wave and are read out in synchronism with the electrocardiogram. The road map images are read out at the same equal time intervals as those of the write mode. The road map image imaged when the electrocardiogram represents the R-wave is read out every time the electrocardiogram represents the R-wave. The subsequent road map images are read out, and the finally imaged road map image is repeatedly read out until the electrocardiogram represents the next R-wave.
PURPOSE:The titled agent for suppressing reduction is PGs caused by administration of drug such as antagonist of histamine H2 acceptor, anti-inflammatory analgesic, etc., by intake of a stimulus, etc., preventing occurrence of peptic ulcer, containing aldioxa as an active ingredient. CONSTITUTION:An agent for suppressing prostaglandins comprising aldioxa (chemical name aluminum dihydroxyallantoinate) as an active ingredient. Aldioxa is found to suppress reduction in PGs caused by administration of drug such as antagonist of histamine H2 acceptor (e.g., cimetidine, ranitidine, etc.), anti-inflammatory agnalgesic (e.g., indomethacin, mefenamic acid, etc.), by intake of drink (e.g., spice, alcohol, etc.), stress, etc., and to have improved protecting action on cell of digestive tube. Especially it is usable for remedying ulcer caused by the drugs, etc. and preventing its recrudescence and recurrence.
(1) Background and Objectives: Mitral regurgitation is a common valve disease requiring surgical repair. Even with satisfactory results, repair techniques may underlie subjectivity and variability and require long learning curves. A novel approach, the "Roman Arch" technique, may ease the technical burden. This study assessed an automated suturing device's feasibility and time efficiency for a proposed simplified technique. (2) Materials and Methods: Using the MiStitch™ and MiKnot™ devices (LSI Solutions, Inc., Victor, NY, USA), the suture pattern was performed in a cadaver model. Three surgeons with different expertise levels conducted the procedures. Repair and suture placement times were recorded and analyzed. (3) Results: The modified "Roman Arch" repair was completed on all ten human heart specimens with an average total repair time of 3:01 ± 00:59 min and a trend toward reduced times as experience increased. The study confirmed the technical feasibility with 90% of the attempts rated as rather satisfactory or very satisfactory. (4) Conclusions: The MiStitch™ system effectively facilitated the modified "Roman Arch" repair in an ex vivo setting, suggesting its potential to reduce the technical complexity of mitral valve repairs. Further studies are needed to confirm its efficacy and safety in clinical practice.
A problem to be solved is to provide an orally ingestible composition which promotes the production of adiponectin and which is free from safety issues such as side effects and toxicity. An adiponectin production promoting composition is prepared which comprises salmon milt extract, brewer's yeast extract, avian collagen, and yeast containing mineral and having an adiponectin production promoting activity. Preferably, the salmon milt extract comprises low molecular weight components obtained by enzymatic degradation of salmon milt into oligonucleotides and oligopeptides. Preferably, the brewer's yeast extract comprises 50 to 80% of RNA. Preferably, the yeast containing mineral comprises, in dry yeast, 2 to 3% of zinc, 0.3 to 0.5% of copper, and 0.01 to 0.02% of selenium. Preferably, the adiponectin production promoting composition comprises 16 to 17 parts by mass of the brewer's yeast extract, 33 to 34 parts by mass of the avian collagen, and 22 to 23 parts by mass of the yeast containing mineral per 100 parts by mass of the salmon milt extract.
The invention relates to a preparation method and application of a tissue in situ high-expression ILK (integrin linked kinase) protein carrier. According to the technical scheme of the invention, an expression vector comprises the gene for coding human ILK protein, and the gene sequences comprise the nucleotide sequence showed as the SEQ ID No. 1 and the nucleotide sequence showed as the SEQ ID No. 2. The invention overcomes the defects that the patients taking the medicament for treating chronic heart failure can still be inevitably subjected to the end-stage heart failure and the CRT (cardiac resynchronization therapy) is extremely expensive and can only take effect on the patients with asynchronous right and left ventricular contraction. The medicament transfects specifically in the focal tissue, has high transfection efficiency, has minimal toxicity to the infected cells, is easy to operate and causes a few complications. The CD45 positive cells in the myocardium of the ILK treatment group are reduced significantly so that the high-expression ILK can inhibit the inflammatory cell from infiltrating to the local tissues. The medicament can not lead to the specific damage, the formation of the tumor and the deformity and is non-toxic.
The invention discloses a Metal Organic Framework (MOF) microneedle patch with a core-shell structure, a preparation method and application thereof. The invention provides a preparation method of MOF (Metal organic framework) micro-needles, which can be used for preparing various MOF micro-needles. Firstly, the invention designs the shape, the size, the distribution density and the like of the microneedle female die, and prepares the microneedle reverse die according to the shape, the size, the distribution density and the like. And then, mixing the matrix material with the MOF, and preparing the micro-needle array with the core-shell structure by a process combining a mold-turning method and a layer-by-layer assembling method, so that the problems of high brittleness and poor mechanical strength of the MOF are solved. The MOF microneedles can penetrate skin tissue and can be used for subcutaneous sensing, drug delivery and the like. The preparation method has the advantages of low cost, convenience in operation, batch production and the like. The MOF material has an ultrahigh specific surface area and a natural pore structure, and can identify, adsorb and encapsulate guest molecules, so that the MOF microneedle has a very high commercial application prospect in the fields of transdermal drug delivery, molecular identification, biosensing, living body imaging and the like.